Table 5.
Pharmacokinetic parameters of intravenous iron–carbohydrate complexes.
| Parameter | Sodium Ferric Gluconate [9] | Iron Sucrose [9] | Ferric Carboxymaltose [9] | Ferumoxytol [9] | Ferric Derisomaltose [22] | Iron Dextran [19] |
|---|---|---|---|---|---|---|
| Dosage used for PK characteristics, mg Fe | 125 | 100 | 100/1000 | 316 | 1000 | NA |
| Terminal t1/2, h | 1.42 | 5.3 | 7.4/9.4 | 14.7 | 27 | 20 |
| Cmax, mg Fe/L | 20.6 | 35.5 | 37/331 | 130 | 408 | NA |
| AUC, mg Fe/L*h | 43.7 | 83.3 | 333/6277 | 2912 | 17730 | NA |
| AUC, standardized for a dose of 100 mg Fe, mg Fe/L*h | 35.0 | 83.3 | 333/627 | 922 | 1773 | NA |
| CL, L/h | 2.99 | 1.23 | 0.26/0.16 | 0.11 | NA | NA |
| IVIP-Fe * cmax (mmol/L) tmax (h) t1/2 (h) AUC0-inf (h*mmol/L) |
0.85 ± 0.17 0.35 (0.33–0.37) 3.43 ± 1.55 2.59 ± 0.5 |
1.16 ± 0.09 0.34 (0.33–0.7) 6.82 ± 1.93 12.39 ± 1.2 |
1.29 ± 0.1 0.67 (0.33–6) 20.3 ± 2.27 36.76 ± 4.9 |
PK: pharmacokinetics; Cmax: maximum serum concentration; AUC: area under the curve; CL: clearance; IVIP: intravenous iron–carbohydrate complex preparation; tmax: time to Cmax. * IVIP-Fe estimates drug bound iron in serum by subtracting transferrin bound iron from total serum iron [43]. All results are mean ± SD except for tmax (mean (min–max)). Dose administered: 200 mg Fe.